Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Electric pulses and chemo aim to stop pancreatic cancer return

NCT ID NCT04281290

Disease control Sponsor: University Medical Centre Ljubljana Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests whether applying electrochemotherapy (electric pulses plus the drug bleomycin) to the area where a pancreatic tumor was removed can lower the chance of cancer coming back. Ten patients with resectable pancreatic cancer will receive the treatment during surgery. The main goal is to check safety and see if it reduces local recurrence.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
bleomycin
What this could lead to
If it works, this could point toward a way to reduce local recurrence after pancreatic cancer surgery.
What could go wrong
This is a very early, small trial (10 patients) testing safety and feasibility. It may not show a clear benefit, and there are risks from surgery and the electrochemotherapy procedure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

10 people

The number who actually took part.

Started

Jul 2020

Expected to finish

May 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients with resectable pancreatic cancer. 2. Histologically confirmed and/or based on radiological imaging and laboratory tests confirmed pancreatic cancer by multidisciplinary team for pancreatic tumors. 3. Age more than 18. 4. Life expectancy more than 3 months. 5. Performance status - Karnofsky ≥ 70 or WHO \< or 2. 6. Treatment free interval 2-5 weeks, depending on the drugs used. 7. Patient must be mentally capable of understanding the information given. 8. Patient must give informed consent. 9. Patient must be discussed at the multidisciplinary team for pancreatic tumors before entering the trial. Exclusion Criteria: 1. Secondary primary tumor, except surgically treated noninvasive cancer of cervix, or surgically or irradiated basal cell carcinoma. 2. Proven visceral, bone or diffuse metastases. 3. Life-threatening infection and/or heart failure and/or liver failure and/or renal failure (creatinine more than 150 µmol/L) other severe systemic pathologies. 4. Significant reduction in respiratory function. 5. Age less than 18 years. 6. Cumulative dose of 250 mg/m2 bleomycin received. 7. Allergic reaction to bleomycin. 8. Patients with epilepsy. 9. Patients with arrhythmias. 10. Patients with heart failure or pacemaker. 11. Pregnancy. 12. Patient incapable of understanding the aim of the study or disagree with the entering into the clinical study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pancreas cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pancreas cancer

Contacts and locations

Locations

  • University Medical Centre Ljubljana, Ljubljana, Slovenia

    Ljubljana, 1000, Slovenia

More trials for these conditions

Other studies related to the condition(s) this trial covers.